Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis

References

• Alliance for Audiited Media. (2016). Top 25 U.S. Newspapers for March 2013. Retrieved from http://auditedmedia.com/news/research-and-data/top-25-us-newspapers-for-march-2013
   Google Scholar
• Bartlett, C., Sterne, J., & Egger, M. (2002). What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. BMJ, 325, 81–84. doi:10.1136/bmj.325.7355.81
   PubMed Web of Science ®Google Scholar
• Daley, C., McNiel, D., & Binder, R. (2011). “I did what?” Zolpidem and the courts. The Journal of the American Academy of Psychiatry and the Law, 39(4), 535–542.
   PubMed Web of Science ®Google Scholar
• Dean, A., Hendy, A., & McGuire, T. (2007). Antidepressants in children and adolescents—Changes in utilisation after safety warnings. Pharmacoepidemiology and Drug Safety, 16, 1048–1053. doi:10.1002/(ISSN)1099-1557
   PubMed Web of Science ®Google Scholar
• Dusetzina, S., Higashi, A., Dorsey, E., Conti, R., Huskamp, H. A., Zhu, S., … Alexander, G. C. (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care, 50, 466–478. doi:10.1097/MLR.0b013e318245a160
   PubMed Web of Science ®Google Scholar
• Entwistle, V. (1995). Reporting research in medical journals and newspapers. BMJ, 310, 920–923. doi:10.1136/bmj.310.6984.920
   PubMed Web of Science ®Google Scholar
• Feinstein, A., & Cicchetti, D. (1990). High agreement but low Kappa: I. the problems of two paradoxes. Journal of Clinical Epidemiology, 43, 543–549. doi:10.1016/0895-4356(90)90158-L
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2014, July 24). Drug safety and availability. Retrieved from http://www.fda.gov/Drugs/DrugSafety/
   Google Scholar
• Food and Drug Administration. (2013, May 14). Drug safety communication: FDA approves new label changes and dosing for Zolpidem products and a recommendation to avoid driving the day after using Ambien CR. Retrieved March 23, 2016, from http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm
   Google Scholar
• Food and Drug Administration. (2013, January 10). Drug safety communication: Risk of next morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Retrieved from http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf
   Google Scholar
• Hoque, R. A. C. Jr. (2009). Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: Fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine, 5(5), 471–476.
   PubMed Web of Science ®Google Scholar
• InCites Journal Citation Reports. (2016). Thomson Reuters. Retrieved from http://thomsonreuters.com/en/products-services/scholarly-scientific-research/research-management-and-evaluation/journal-citation-reports.html
   Google Scholar
• Irwin, D., & Palmer, L. (2014, April). When gender matters: impact of an FDA safety warning on dispensed zolpidem dose Ann Arbor, MI: Truven Health Analytics.
   Google Scholar
• Kesselheim, A. S., Campbell, E. G., Schneeweiss, S., Rausch, P. M., Lappin, B., Zhou, E., … Avorn, J. (2015). Methodological approaches to evaluate the impact of FDA Drug Safety Communications. Drug Safety, 38(6), 565–575. doi:10.1007/s40264-015-0291-y
   PubMed Web of Science ®Google Scholar
• Landis, J., & Koch, G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159–174. doi:10.2307/2529310
   PubMed Web of Science ®Google Scholar
• Piening, S., Haaijer-Ruskamp, F., De Vries, J. T., Van Der Elst, M. E., De Graeff, P. A., Straus, S. M., & Mol, P. G. (2012). Impact of safety-related regulatory action on clinical practice. A systematic review. Drug Safety, 35, 373–385. doi:10.2165/11599100-000000000-00000
   PubMed Web of Science ®Google Scholar
• Reber, K., Piening, S., Wieringa, J., Straus, S. M. J. M, Raine, J. M., De Graeff, P. A., … Mol, P. G. M. (2013). When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines. Clinical Pharmacology & Therapeutics, 93, 360–365.
   PubMed Web of Science ®Google Scholar
• De Semir, V., Ribas, C., & Revuelta, G. (1988). Press releases of science journal articles and subsequent newspaper stories on the same topic. JAMA: Journal of the American Medical Association, 280, 294–295
   Web of Science ®Google Scholar
• Stryker, J. (2002). Reporting medical information: Effects of press releases and newsworthiness on medical journal articles’ visibility in the news media. Preventive Medicine, 35, 519–530. doi:10.1006/pmed.2002.1102
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2013, May 1). Emergency department visits for adverse reactions involving the insomnia medication zolpidem. Retrieved from http://www.samhsa.gov/data/sites/default/files/DAWN079/DAWN079/sr079-Zolpidem.htm
   Google Scholar
• Van Trigt, A. M., Haaijer-Ruskamp, F. M., Willems, J., & Tromp, T. F. (1994). Journalists and their sources of ideas and information on medicines. Social Science & Medicine, 38, 637–643. doi:10.1016/0277-9536(94)90261-5
   PubMed Web of Science ®Google Scholar
• Woloshin, S., Schwartz, L., Andrews, A., & Stukel, T. (2012). Influence of medical journal press releases on the quality of associated newspaper coverage: Retrospective cohort study. BMJ. doi:10.1136/bmj.d8164
   Web of Science ®Google Scholar